Mercury Laboratories
Market Cap
₹284.8m
Last Updated
2019/10/23 12:50 UTC
Data Sources
Company Financials
Executive Summary
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare in Asia, Africa, the Far East, and internationally.
Snowflake
Fundamentals
Flawless balance sheet and fair value.
Share Price & News
How has Mercury Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
4.0%
538964
4.0%
IN Pharmaceuticals
2.4%
IN Market
1 Year Return
-38.2%
538964
-13.9%
IN Pharmaceuticals
8.0%
IN Market
Return vs Industry: 538964 underperformed the Indian Pharmaceuticals industry which returned -13.9% over the past year.
Return vs Market: 538964 underperformed the Indian Market which returned 8% over the past year.
Shareholder returns
| 538964 | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.0% | 4.0% | 2.4% |
| 30 Day | -10.1% | -2.8% | 2.5% |
| 90 Day | -6.3% | 0.7% | 3.6% |
| 1 Year | -37.8%-38.2% | -13.1%-13.9% | 10.3%8.0% |
| 3 Year | -53.4%-54.0% | -24.6%-26.2% | 22.3%16.0% |
| 5 Year | n/a | -10.2%-12.9% | 42.8%29.3% |
Price Volatility Vs. Market
How volatile is Mercury Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Mercury Laboratories undervalued compared to its fair value and its price relative to the market?
9.33x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 538964 (₹235) is trading above our estimate of fair value (₹204.54)
Significantly Below Fair Value: 538964 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 538964 is good value based on its PE Ratio (9.3x) compared to the Pharmaceuticals industry average (15.6x).
PE vs Market: 538964 is good value based on its PE Ratio (9.3x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 538964's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 538964 is good value based on its PB Ratio (1x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Mercury Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
11.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 538964's forecast earnings growth (11.9% per year) is above the savings rate (7.6%).
Earnings vs Market: 538964's earnings (11.9% per year) are forecast to grow slower than the Indian market (18.4% per year).
High Growth Earnings: 538964's earnings are forecast to grow, but not significantly.
Revenue vs Market: Insufficient data to determine if 538964's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if 538964's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 538964's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Mercury Laboratories performed over the past 5 years?
-5.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 538964's earnings have declined by -5.3% per year over the past 5 years.
Accelerating Growth: 538964's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 538964 had negative earnings growth (-27.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.2%).
Return on Equity
High ROE: 538964's Return on Equity (10.4%) is considered low.
Return on Assets
ROA vs Industry: 538964's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 538964's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Mercury Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 538964's short term assets (₹319.0M) exceeds its short term liabilities (₹169.2M)
Long Term Liabilities: 538964's short term assets (319.0M) exceeds its long term liabilities (114.1M)
Debt to Equity History and Analysis
Debt Level: 538964's debt to equity ratio (29.4%) is considered satisfactory
Reducing Debt: 538964's debt to equity ratio has reduced from 72.7% to 29.4% over the past 5 years.
Debt Coverage: 538964's debt is well covered by operating cash flow (61.4%).
Interest Coverage: 538964's interest payments on its debt are well covered by EBIT (3.4x coverage).
Balance Sheet
Inventory Level: 538964 has a high level of physical assets or inventory.
Debt Coverage by Assets: 538964's debt is covered by short term assets (assets are 3.752090x debt).
Next Steps
Dividend
What is Mercury Laboratories's current dividend yield, its reliability and sustainability?
0.64%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 538964's dividend (0.64%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 538964's dividend (0.64%) is low compared to the top 25% of dividend payers in the Indian market (2.41%).
Stable Dividend: Whilst dividend payments have been stable, 538964 has been paying a dividend for less than 10 years.
Growing Dividend: 538964 has only been paying a dividend for 4 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (6%), 538964's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Mercury Laboratories's salary, the management and board of directors tenure and is there insider trading?
4.6yrs
Average board tenure
CEO
Rajendra Shah (67yo)
0yrs
Tenure
₹2,181,181
Compensation
Mr. Rajendra Ramanlal Shah has been the Managing Director of Mercury Laboratories Limited since March 31, 1992 and serves as its Chief Executive Officer and Chairman of the Board. Mr. Shah has experience o ...
CEO Compensation Analysis
Compensation vs. Market: Rajendra's total compensation ($USD30.80K) is too low to compare against companies of similar size in the Indian market ($USD33.85K).
Compensation vs Earnings: Rajendra's compensation has been consistent with company performance over the past year.
Board Age and Tenure
4.6yrs
Average Tenure
66.5yo
Average Age
Experienced Board: 538964's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Rajendra Shah (67yo)
Chairman
- Tenure: 0yrs
- Compensation: ₹2.18m
Paresh Mistry (50yo)
Works Manager & Director
- Tenure: 2yrs
- Compensation: ₹17.50k
Kinjal Khandelwal
Company Secretary
- Tenure: 0.3yrs
Board Members
Rajendra Shah (67yo)
Chairman
- Tenure: 0yrs
- Compensation: ₹2.18m
Dilip Shah (65yo)
Non-Executive Director
- Tenure: 37.7yrs
- Compensation: ₹5.00k
Poornima Karvat (72yo)
Non Executive Independent Director
- Tenure: 4.6yrs
- Compensation: ₹18.50k
Bharat Mehta (66yo)
Non Executive Independent Director
- Tenure: 4.4yrs
- Compensation: ₹17.50k
Divyakant Zaveri (71yo)
Non Executive Independent Director
- Tenure: 5.3yrs
- Compensation: ₹36.00k
Paresh Mistry (50yo)
Works Manager & Director
- Tenure: 2yrs
- Compensation: ₹17.50k
Company Information
Mercury Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mercury Laboratories Limited
- Ticker: 538964
- Exchange: BSE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹284.760m
- Shares outstanding: 1.20m
- Website: https://www.mercurylabs.com
Number of Employees
Location
- Mercury Laboratories Limited
- 2/13-14, Gorwa Industrial Estate
- Gorwa Road
- Vadodara
- Gujarat
- 390016
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 538964 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Feb 2015 |
Biography
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare in Asia, Africa, the Far East, and in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 12:50 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.